A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or Obesity

NCT07768813 · Not yet recruiting

Last updated 2026-08-27

This study compares how two different versions of the drug survodutide are absorbed in the body when injected into healthy adults, as well as those with overweight or obesity.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 44 people Planned (estimated).

Who can join Ages 18–55 · all sexes Healthy volunteers accepted.

Timeline Started 2026-09 · est. completion 2026-12

Where 1 site · Germany

What this study is testing ClinicalTrials.gov NCT07768813 ↗

Description as written by the study sponsor.

The main objective of this trial is to establish the bioequivalence of survodutide in a pre-filled syringe (reference product \[formulation A\]) and in a vial (test product \[formulation B2\]) in male and female trial participants who are healthy or otherwise healthy with overweight/obesity, following subcutaneous administration.

Treatments tested

Survodutide formulation A also known as BI 456906 Combination Product

Pre-filled pen
Survodutide formulation B2 also known as BI 456906 Drug

Survodutide formulation B2

Main thing measured	Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)
Sponsor	Boehringer Ingelheim
Conditions studied	Healthy, Obesity
GLP-1 drugs	survodutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07768813 ↗